MedTrace Logo

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System

NCT07334691 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-11

No results posted yet for this study

Summary

This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

Conditions

  • Tricuspid Regurgitation

Interventions

DEVICE

Cardiovalve TR valve replacement System

Cardiovalve Tricuspid Valve Replacement system

Sponsors & Collaborators

  • Cardiovalve Ltd.

    lead INDUSTRY

Principal Investigators

  • Georg Nickenig · Bonn Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2028-06-30
Completion
2033-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07334691 on ClinicalTrials.gov